Casdin Capital, LLC Clovis Oncology, Inc. Transaction History

Casdin Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$11.63 - $32.67 $2.73 Million - $7.68 Million	-235,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $440,550 - $742,200	15,000 Added 6.82%	235,000 $6.9 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $1.79 Million - $2.65 Million	42,500 Added 23.94%	220,000 $10 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $2.51 Million - $3.39 Million	50,000 Added 39.22%	177,500 $9.37 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $8.56 Million - $10.8 Million	127,500	127,500 $10.5 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.